Chinese

Global Single Cell Genome Sequencing Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 6, 2023
Health, Genetics, Science, Research, Oncology, Prostate, Chinese, Conditional sentence, Prevalence, Investment, Traction, Application, Breast cancer, Patient, PCR, Arthritis, USD, Workflow, NIH, Growth, NGS, Biomarker, Diabetes, Real-time, Cancer, Immunology

The "Single Cell Genome Sequencing Market Size, Share & Trends Analysis By Product Type (Instruments, Reagents), By Disease Area (Cancer, Immunology), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single Cell Genome Sequencing Market Size, Share & Trends Analysis By Product Type (Instruments, Reagents), By Disease Area (Cancer, Immunology), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global single cell genome sequencing market size is anticipated to reach USD 7.55 billion by 2030.
  • Active participation and contribution of market players toward product upgradation play an important role in the growth of the market.
  • Moreover, the emergence of next-generation sequencing (NGS) has helped the market gain tremendous traction over the past few years.

BizWorld Names Tech Diplomacy Leader Keith Krach 2023 Riskmaster of the Year

Retrieved on: 
Thursday, November 30, 2023
Thought Leadership, Entrepreneur, Professional Services, Primary, Secondary, Consumer, Education, Training, Business, CHIPS, National security advisor, Draper University, Purdue University, Uyghur, Bomber, Opportunity International, Character, Robotics, Telecommunications, Computer, Entrepreneurship, Atrocity, Science, Risk, Computer History Museum, State, Silicon, Student, Multimedia, General Motors, Senate, Trust, Communism, TSMC, Movement, Public policy, Friends, Genocide, SAP Ariba, Freedom, Authoritarianism, Democracy, Family, Nobel Peace Prize, City Year, Bipartisanship, Mechanical, DocuSign, Renewable energy, Film industry, Cryptocurrency, Chinese, Krach

BizWorld.org, a global non-profit that provides entrepreneurship education programs to youth, has named Keith Krach , Chairman of the Krach Institute for Tech Diplomacy at Purdue , former Under Secretary of State and Silicon Valley entrepreneur its 2023 Riskmaster of the Year.

Key Points: 
  • BizWorld.org, a global non-profit that provides entrepreneurship education programs to youth, has named Keith Krach , Chairman of the Krach Institute for Tech Diplomacy at Purdue , former Under Secretary of State and Silicon Valley entrepreneur its 2023 Riskmaster of the Year.
  • The award is in recognition of Krach's fearless leadership and transformative impact, spanning business, technology, academia, mentorship, economic diplomacy, social causes and national security.
  • “Keith embodies the essential qualities of a Riskmaster through his historic achievements, including architecting the Bipartisan CHIPS and Science Act that secured a $280 billion in funding for the tech industry.
  • Krach continues to shape the future of technology and public policy as leader of the congressionally mandated Global Tech Security Commission and co-founder and chairman of the Krach Institute for Tech Diplomacy at Purdue.

Asia Pacific Multi-cancer Early Detection (Liquid Biopsy, Gene Panel, LDT) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023
Research, Oncology, Technology, Hospitals, Artificial Intelligence, Genetics, Science, Biotechnology, Stem Cells, Other Technology, Other Science, Health, Nucleic acid thermodynamics, Prevalence, Liver, Risk, Hospital, Clinical trial, Chinese, Patient, LDT, Multi, USD, Cancer, Diagnosis, Growth, Liquid biopsy, Medical imaging, Pharmaceutical industry

The "Asia Pacific Multi-cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT ), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Multi-cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT ), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to Global Cancer Statistics 2020, nearly half of all cases and around 58.3% of cancer deaths globally in 2020 occurred in the Asia Pacific.
  • There are several limitations to single cancer tests, such as high false-positive rates and optimized sensitivity.
  • It is a USD 200 million joint venture and aims to deliver the MCED test by 2025, priced at USD 200, making early detection available to all.

Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval

Retrieved on: 
Monday, November 20, 2023
Science, Other Science, Biotechnology, Research, Oncology, Health, Medical Devices, Clinical Trials, Shandong University, Woman, OTCQB, Therapy, Peking University, NMPA, Clinical trial, Marketing, Chinese, SMI, Fudan University, Obstetrics, Professor, Medical device

Guided Therapeutics, Inc. (OTCQB: GTHP) announced today the completion of the clinical trial for marketing and sales approval of the Company’s LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration (NMPA).

Key Points: 
  • Guided Therapeutics, Inc. (OTCQB: GTHP) announced today the completion of the clinical trial for marketing and sales approval of the Company’s LuViva Advanced Cervical Scan by the Chinese National Medical Products Administration (NMPA).
  • The study, which included approximately 450 women, was conducted at four prestigious medical institutions, including Shandong University, Fudan University and Peking University.
  • The filing triggers purchase order payments to Guided Therapeutics of approximately $2.2 Million, with additional significant orders for devices and disposables in 2024 and beyond.
  • “We are extremely pleased that the study has reached its completion, and that its results will be filed soon with NMPA,” said Mark Faupel, CEO of Guided Therapeutics.

O'BRIEN: REVOKE PNTR FOR CHINA

Retrieved on: 
Wednesday, December 13, 2023
World Trade Organization, Woman, International Brotherhood of Teamsters, Policy, Chinese, Democrat, Communist party, Strategic competition, PNTR, Teamster, Congress, Drug

Lawmakers have a duty to all Americans to stop outsourcing good union jobs and stop wasting federal tax dollars.

Key Points: 
  • Lawmakers have a duty to all Americans to stop outsourcing good union jobs and stop wasting federal tax dollars.
  • "China flouts rules that the World Trade Organization and others have implemented for competing on a level playing field in a global economy, proving the penalties to curb their unfair practices are useless.
  • U.S. trade policy with China must change.
  • "Millions of good-paying, union jobs have been lost to China over the decades.

LF Edge Project Portfolio Expands Footprint with Two new Community Projects Addressing Different Layers of the Stack, Nexoedge and NanoMQ

Retrieved on: 
Tuesday, December 12, 2023
Telecom, Research, Internet of things, Croquet OS, Real, MQTT, Secrecy, Privacy, Chinese, CUHK, Silicon, Linux Foundation, Secret sharing, Algorithm, Computer science, Ecosystem, EdgeX Foundry, Linux, Central processing unit, Organizational founder, Automation, Breeding, Connectivity, 2600-series (CTA), EMQ, NNG, Communication, Mobile country code, AI, LF, Robotics, Motion, Enterprise, Computer data storage, Mobile phone, Cloud, Engineering, Network

NanoMQ is an ultra-lightweight and blazing-fast Message Queuing Telemetry Transport (MQTT) broker for IoT Edge.

Key Points: 
  • NanoMQ is an ultra-lightweight and blazing-fast Message Queuing Telemetry Transport (MQTT) broker for IoT Edge.
  • It helps users unify critical data in motion and data in use between Edge and Cloud in an efficient manner.
  • "LF Edge continues to grow across the ecosystem, and we are thrilled to welcome Nexoedge and NanoMQ to the project fold," said Arpit Jopshipura, general manager, Networking, Edge and IoT, the Linux Foundation.
  • The Nexoedge team will explore integration opportunities across LF Edge projects by offering the critical edge storage component.

Himalaya Exchange customers launch legal action against the U.S. Department of Justice

Retrieved on: 
Friday, December 8, 2023
Assistant, Hoxhaism, Investment, CCP, FBI, Fraud, Government, Communist party, USD, District court, Justice minister, Cryptocurrency, Audit, Chinese, Himalayas

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- FormerFeds, a distinguished provider of corporate defense and litigation services, has initiated legal action in the U.S. District Court for the Southern District of New York in the case of United States v. Miles Kwok. This action represents over three and half thousand customers whose savings and investments in Himalaya Exchange were frozen by the U.S. Department of Justice (DoJ). 

Key Points: 
  • The legal filing contends that the DoJ's actions were predatory and unlawful, adversely affecting individuals who invested in Himalaya Coin and Himalaya Dollar cryptocurrencies.
  • Plaintiffs assert that the DoJ's alignment with CCP policies and goals has unjustly harmed Himalaya Exchange customers.
  • This action represents over three and half thousand customers whose savings and investments in Himalaya Exchange were frozen by the U.S. Department of Justice (DoJ).
  • The legal action satisfies all the legal requirements and aims to streamline the legal process and ensure a fair resolution for all victims.

The 2023 Understanding China Conference: China Narrative Challenges and Opportunities

Retrieved on: 
Friday, December 8, 2023
Belt, Policy, Monkey King, Chinese, Dean, Foreign Affairs, Council, Cui Tiankai, Conference, Community, Death, Speech, Innovation, Knowledge, Convergence, Interest, Management, State, Shenzhen

Cui Tiankai underscored the necessity of a precise narrative to grasp China's essence.

Key Points: 
  • Cui Tiankai underscored the necessity of a precise narrative to grasp China's essence.
  • He highlighted three widespread mistaken acknowledgement about China's foreign policy: China's strategic global intentions, China's peripheral foreign policy, and China's diplomatic style.
  • Kissinger often said that each visit to China brought fresh insights and knowledge.
  • As a symbol of an era, his passing did not end that era; instead, sparked a new period in international relations."

The 2023 Understanding China Conference: China Narrative Challenges and Opportunities

Retrieved on: 
Friday, December 8, 2023
Belt, Policy, Monkey King, Chinese, Dean, Multimedia, Foreign Affairs, Council, Cui Tiankai, Conference, Community, Death, Speech, Innovation, Knowledge, Convergence, Interest, Management, State, Shenzhen

Cui Tiankai underscored the necessity of a precise narrative to grasp China's essence.

Key Points: 
  • Cui Tiankai underscored the necessity of a precise narrative to grasp China's essence.
  • He highlighted three widespread mistaken acknowledgement about China's foreign policy: China's strategic global intentions, China's peripheral foreign policy, and China's diplomatic style.
  • Kissinger often said that each visit to China brought fresh insights and knowledge.
  • As a symbol of an era, his passing did not end that era; instead, sparked a new period in international relations."

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Retrieved on: 
Wednesday, December 6, 2023
NDA, Dexamethasone, Immunotherapy, NCCN, Disease, Hematology, Proteasome inhibitor, ESMO, Diagnosis, Multiple myeloma, International Myeloma Foundation, Patient, Guideline, Chinese, XPO1, Therapy, Selinexor, Oncology, Growth, CSCO, Pi, HIV disease progression rates, Pharmaceutical industry, Medical device

XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.

Key Points: 
  • XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • XPOVIO® is the world's first oral selective inhibitor of the nuclear export protein XPO1, with regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
  • "Antengene is excited to receive approval of XPOVIO® in Macau, first in the next wave of expected approvals in the APAC."
  • I am glad that XPOVIO® has become the first and only XPO1 inhibitor approved for the treatment of patients with R/R MM in Macau China.